Enliven Therapeutics, Inc.

NASDAQ:ELVN

Biotechnology

Healthcare
$44.89 -0.27%

-$0.12 today

Market cap
$3.30B
Beta
0.40
P/E (TTM)
-28.4
EPS (TTM)
-$1.57
52W Low $14.79High $48.53

Volume 0.75M

Average 1.35M

ELVN Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Enliven Therapeutics, Inc.NASDAQ: ELVN

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue remains negative

Q3 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $60K.

Context

  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $15K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$263K— YoY
LTMSep 2026
$60K— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
263K USD
Year-over-year change
—

Cost of Revenue vs competitors

How ELVN compares with its peers on the latest reported figures

  • ELVN's LTM Sep 2026 cost of revenue of $60K is the 10th highest of the 11 companies compared; the peer median is $6.84M.
ELVN Competitors Peer median
Cost of Revenue for ELVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$429.56M +31.6%+21.6%7.4%
EXELExelixis, Inc.LTM Jul 2026$85.67M +12.8%+13.1%3.5%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$68.99M -65.9%-75.5%666.6%
NUVBNuvation Bio Inc.LTM Jun 2026$10.3M -1.0%—6.1%
RVMDRevolution Medicines, Inc.LTM Jun 2026$9.24M ———
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$4.44M +401.7%—2.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$320K +5.3%——
TYRATyra Biosciences, Inc.LTM Mar 2026$138K +9.5%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$79K +2.6%——
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$60K ———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding ELVN) $6.84M+7.4%+13.1%6.1%

Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000263K
Gross Profit0000(263K)
Gross Margin—————
Research & Development20.47M31.02M64.57M80.78M85.86M
Selling, General & Admin4.29M7.77M18.96M23.78M33.8M
Operating Expenses24.76M38.79M83.53M104.55M119.4M
Depreciation & Amortization115K215K297K317K263K
EBITDA(24.63M)(37.45M)(71.29M)(88.48M)(103.43M)
EBITDA Margin—————
Operating Income(24.76M)(38.79M)(83.53M)(104.55M)(119.66M)
Operating Margin—————
Interest Income22K1.13M11.97M14.89M16.01M
Interest Expense00000
Other Income / Expenses22K1.13M11.95M15.76M15.96M
Income Before Tax(24.74M)(37.66M)(71.58M)(88.79M)(103.69M)
Pre-Tax Margin—————
Income Tax Expense000232K0
Net Income(24.74M)(37.66M)(71.58M)(89.02M)(103.69M)
Net Margin—————
EPS (Basic)(3.17)(6.03)(2.01)(1.89)(1.83)
EPS (Diluted)(3.17)(6.03)(2.01)(1.89)(1.83)
Weighted Avg Shares7.81M6.25M35.55M47.07M56.66M
Weighted Avg Shares (Diluted)7.82M6.25M35.55M47.07M56.66M

Enliven Therapeutics, Inc.

NASDAQ:ELVN

Intrinsic Alpha fair value

Locked

Current Price

$44.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.